Innovation Pharmaceuticals Inc (IPIX)

[BonelessCat]

While I agree that BP is more interested in individual lines, the heavy lifting for developing lines and proving them is pretty much completed. Also, Brilacidin seems to require very little reformulation for both its anti-inflammatory and antibiotic wide ranged applications. Adapting the application medium is less challenging and cheaper if the molecule remains the same, which is not the case for the vast majority of drug platforms.

That said, a Brilacidin pill is in the second category, reformulation and possibly needing a courier or cleaver. However, BP specializing in one application of Brilacidin might not be interested in the added expense of developing new frontiers and market pathways, leaving those indications to others with well-worn distribution systems. Nonetheless, I'm fairly sure there is at least one BP giant entertaining the idea of paying a few billion to open or reopen antibiotics and anti inflammatory lines from a single platform of mimetics.